Targeted electro-delivery of oligonucleotides for RNA interference: SiRNA and antimiR

Advanced Drug Delivery Reviews

Volumn 81, Issue , 2015, Pages 161-168

  Chabot, Sophie ^a,b,c   Teissié, Justin ^a,b   Golzio, Muriel ^a,b  

^a INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c UROsphere ^*  (France)

Author keywords

Electropermeabilization; Electroporation; LNA; RNAi; SiRNA

Indexed keywords

CELL MEMBRANES; OLIGONUCLEOTIDES; RNA;

ELECTROPERMEABILIZATION; ELECTROPORATION; LNA; RNAI; SIRNA;

NUCLEIC ACIDS;

OLIGOMER; OLIGONUCLEOTIDE; SMALL INTERFERING RNA; MICRORNA;

BIOPHYSICS; CELL MEMBRANE; CELLULAR DISTRIBUTION; CHEMICAL STRUCTURE; COMPUTER MODEL; ELECTRIC FIELD; ELECTRODE; ELECTRON TRANSPORT; ELECTROPHORESIS; INTRACELLULAR TRANSPORT; NONHUMAN; REVIEW; RNA INTERFERENCE; ANIMAL; ELECTROPORATION; GENETICS; HUMAN; METABOLISM; PROCEDURES;

ANIMALS; CELL MEMBRANE; ELECTROPORATION; HUMANS; MICRORNAS; OLIGONUCLEOTIDES; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84922325410     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.05.002     Document Type: Review

References (107)

1. Bumcrot D., Manoharan M., Koteliansky V., Sah D.W. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat. Chem. Biol. 2006, 2:711-719.
2. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
3. Lee R.C., Feinbaum R.L., Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75:843-854.
4. Tong A.W., Zhang Y.A., Nemunaitis J. Small interfering RNA for experimental cancer therapy. Curr. Opin. Mol. Ther. 2005, 7:114-124.
5. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
6. Carthew R.W., Sontheimer E.J. Origins and mechanisms of miRNAs and siRNAs. Cell 2009, 136:642-655.
7. Ambros V. microRNAs: tiny regulators with great potential. Cell 2001, 107:823-826.
8. Place R.F., Li L.C., Pookot D., Noonan E.J., Dahiya R. MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:1608-1613.
9. Long J., Wang Y., Wang W., Chang B.H., Danesh F.R. Identification of microRNA-93 as a novel regulator of vascular endothelial growth factor in hyperglycemic conditions. J. Biol. Chem. 2010, 285:23457-23465.
10. da Costa Martins P.A., Salic K., Gladka M.M., Armand A.S., Leptidis S., El Azzouzi H., Hansen A., Coenen-de Roo C.J., Bierhuizen M.F., van der Nagel R., van Kuik J., de Weger R., de Bruin A., Condorelli G., Arbones M.L., Eschenhagen T., De Windt L.J. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nat. Cell Biol. 2010, 12:1220-1227.
11. He L., Thomson J.M., Hemann M.T., Hernando-Monge E., Mu D., Goodson S., Powers S., Cordon-Cardo C., Lowe S.W., Hannon G.J., Hammond S.M. A microRNA polycistron as a potential human oncogene. Nature 2005, 435:828-833.
12. Yu Z., Wang L., Wang C., Ju X., Wang M., Chen K., Loro E., Li Z., Zhang Y., Wu K., Casimiro M.C., Gormley M., Ertel A., Fortina P., Chen Y., Tozeren A., Liu Z., Pestell R.G. Cyclin D1 induction of Dicer governs microRNA processing and expression in breast cancer. Nat. Commun. 2013, 4:2812.
13. Stenvang J., Lindow M., Kauppinen S. Targeting of microRNAs for therapeutics. Biochem. Soc. Trans. 2008, 36:1197-1200.
14. Brodersen P., Voinnet O. Revisiting the principles of microRNA target recognition and mode of action. Nat. Rev. Mol. Cell Biol. 2009, 10:141-148.
15. Khan A.A., Betel D., Miller M.L., Sander C., Leslie C.S., Marks D.S. Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat. Biotechnol. 2009, 27:549-555.
16. Burchard J., Jackson A.L., Malkov V., Needham R.H., Tan Y., Bartz S.R., Dai H., Sachs A.B., Linsley P.S. MicroRNA-like off-target transcript regulation by siRNAs is species specific. RNA 2009, 15:308-315.
17. Ebert M.S., Neilson J.R., Sharp P.A. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat. Methods 2007, 4:721-726.
18. Haraguchi T., Ozaki Y., Iba H. Vectors expressing efficient RNA decoys achieve the long-term suppression of specific microRNA activity in mammalian cells. Nucleic Acids Res. 2009, 37:e43.
19. Wang X., Han L., Zhang A., Wang G., Jia Z., Yang Y., Yue X., Pu P., Shen C., Kang C. Adenovirus-mediated shRNAs for co-repression of miR-221 and miR-222 expression and function in glioblastoma cells. Oncol. Rep. 2011, 25:97-105.
20. Sigoillot F.D., King R.W. Vigilance and validation: keys to success in RNAi screening. ACS Chem. Biol. 2011, 6:47-60.
21. Cheng C.J., Saltzman W.M., Slack F.J. Canonical and non-canonical barriers facing antimiR cancer therapeutics. Curr. Med. Chem. 2013, 20:3582-3593.
22. Lennox K.A., Behlke M.A. Chemical modification and design of anti-miRNA oligonucleotides. Gene Ther. 2011, 18:1111-1120.
23. Corey D.R. Chemical modification: the key to clinical application of RNA interference?. J. Clin. Invest. 2007, 117:3615-3622.
24. Braasch D.A., Jensen S., Liu Y., Kaur K., Arar K., White M.A., Corey D.R. RNA interference in mammalian cells by chemically-modified RNA. Biochemistry 2003, 42:7967-7975.
25. Kumar R., Singh S.K., Koshkin A.A., Rajwanshi V.K., Meldgaard M., Wengel J. The first analogues of LNA (locked nucleic acids): phosphorothioate-LNA and 2'-thio-LNA. Bioorg. Med. Chem. Lett. 1998, 8:2219-2222.
26. Krutzfeldt J., Rajewsky N., Braich R., Rajeev K.G., Tuschl T., Manoharan M., Stoffel M. Silencing of microRNAs in vivo with 'antagomiRs'. Nature 2005, 438:685-689.
27. Kaur H., Babu B.R., Maiti S. Perspectives on chemistry and therapeutic applications of locked nucleic acid (LNA). Chem. Rev. 2007, 107:4672-4697.
28. Crinelli R., Bianchi M., Gentilini L., Magnani M. Design and characterization of decoy oligonucleotides containing locked nucleic acids. Nucleic Acids Res. 2002, 30:2435-2443.
29. Wahlestedt C., Salmi P., Good L., Kela J., Johnsson T., Hökfelt T., Broberger C., Porreca F., Lai J., Ren K., Ossipov M., Koshkin A., Jakobsen N., Skouv J., Oerum H., Jacobsen M.H., Wengel J. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc. Natl. Acad. Sci. USA 2000, 97:5633-5638.
30. Wengel J., Vester B., Lundberg L.B., Douthwaite S., Sørensen M.D., Babu B.R., Gait M.J., Arzumanov A., Petersen M., Nielsen J.T. LNA and alpha-L-LNA: towards therapeutic applications. Nucleosides Nucleotides Nucleic Acids 2003, 22:601-604.
31. Lanford R.E., Hildebrandt-Eriksen E.S., Petri A., Persson R., Lindow M., Munk M.E., Kauppinen S., Ørum H. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010, 327:198-201.
32. Garzon R., Marcucci G., Croce C.M. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat. Rev. Drug Discov. 2010, 9:775-789.
33. Miele E., Spinelli G.P., Miele E., Di Fabrizio E., Ferretti E., Tomao S., Gulino A. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Int. J. Nanomedicine 2012, 7:3637-3657.
34. Castanotto D., Rossi J.J. The promises and pitfalls of RNA-interference-based therapeutics. Nature 2009, 457:426-433.
35. Cemazar M., Golzio M., Escoffre J.M., Couderc B., Sersa G., Teissie J. In vivo imaging of tumor growth after electrochemotherapy with cisplatin. Biochem. Biophys. Res. Commun. 2006, 348:997-1002.
36. Cemazar M., Golzio M., Sersa G., Hojman P., Kranjc S., Mesojednik S., Rols M.P., Teissie J. Control by pulse parameters of DNA electrotransfer into solid tumors in mice. Gene Ther. 2009, 16:635-644.
37. Golzio M., Mazzolini L., Ledoux A., Paganin A., Izard M., Hellaudais L., Bieth A., Pillaire M.J., Cazaux C., Hoffmann J.S., Couderc B., Teissie J. In vivo gene silencing in solid tumors by targeted electrically mediated siRNA delivery. Gene Ther. 2007, 14:752-759.
38. Coster H.G. A quantitative analysis of the voltage-current relationships of fixed charge membranes and the associated property of "punch-through". Biophys. J. 1965, 5:669-686.
39. Teissie J., Golzio M., Rols M.P. Mechanisms of cell membrane electropermeabilization: a mini-review of our present (lack of ?) knowledge. Biochim. Biophys. Acta 2005, 1724:270-280.
40. Wells D.J. Gene therapy progress and prospects: electroporation and other physical methods. Gene Ther. 2004, 11:1363-1369.
41. Heller L.C., Heller R. In vivo electroporation for gene therapy. Hum. Gene Ther. 2006, 17:890-897.
42. Mlakar V., Todorovic V., Cemazar M., Glavac D., Sersa G. Electric pulses used in electrochemotherapy and electrogene therapy do not significantly change the expression profile of genes involved in the development of cancer in malignant melanoma cells. BMC Cancer 2009, 9:299.
43. Gothelf A., Mir L.M., Gehl J. Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat. Rev. 2003, 29:371-387.
44. Sersa G., Miklavcic D., Cemazar M., Rudolf Z., Pucihar G., Snoj M. Electrochemotherapy in treatment of tumors. Eur. J. Surg. Oncol. 2008, 34:232-240.
45. Daud A.I., DeConti R.C., Andrews S., Urbas P., Riker A.I., Sondak V.K., Munster P.N., Sullivan D.M., Ugen K.E., Messina J.L., Heller R. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J. Clin. Oncol. 2008, 26:5896-5903.
46. Bodles-Brakhop A.M., Heller R., Draghia-Akli R. Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments. Mol. Ther. 2009, 17:585-592.
47. Braasch D.A., Liu Y., Corey D.R. Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design. Nucleic Acids Res. 2002, 30:5160-5167.
48. Corsten M.F., Miranda R., Kasmieh R., Krichevsky A.M., Weissleder R., Shah K. MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. Cancer Res. 2007, 67:8994-9000.
49. Marcusson E.G., Bhat B., Manoharan M., Bennett C.F., Dean N.M. Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus. Nucleic Acids Res. 1998, 26:2016-2023.
50. Zhang Y., Qu Z., Kim S., Shi V., Liao B., Kraft P., Bandaru R., Wu Y., Greenberger L.M., Horak I.D. Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection. Gene Ther. 2011, 18:326-333.
51. Wolf H., Rols M.P., Neumann E., Teissié J. Control by pulse parameters of electric field mediated gene transfer in mammalian cells. Biophys. J. 1994, 66:524-531.
52. Golzio M., Teissie J., Rols M.P. Direct visualization at the single-cell level of electrically mediated gene delivery. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:1292-1297.
53. Escoffre J.M., Portet T., Wasungu L., Teissie J., Dean D., Rols M.P. What is (still not) known of the mechanism by which electroporation mediates gene transfer and expression in cells and tissues. Mol. Biotechnol. 2009, 41:286-295.
54. Pucihar G., Kotnik T., Miklavcic D., Teissié J. Kinetics of transmembrane transport of small molecules into electropermeabilized cells. Biophys. J. 2008, 95:2837-2848.
55. Rols M.P., Femenia P., Teissie J. Long-lived macropinocytosis takes place in electropermeabilized mammalian cells. Biochem. Biophys. Res. Commun. 1995, 208:26-35.
56. Morgan W.F., Day J.P. The introduction of proteins into mammalian cells by electroporation. Methods Mol. Biol. 1995, 48:63-71.
57. Weil D., Garçon L., Harper M., Duménil D., Dautry F., Kress M. Targeting the kinesin Eg5 to monitor siRNA transfection in mammalian cells. Biotechniques 2002, 33:1244-1248.
58. Wilson J.A., Jayasena S., Khvorova A., Sabatinos S., Rodrigue-Gervais I.G., Arya S., Sarangi F., Harris-Brandts M., Beaulieu S., Richardson C.D. RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:2783-2788.
59. Dunne J., Drescher B., Riehle H., Hadwiger P., Young B.D., Krauter J., Heidenreich O. The apparent uptake of fluorescently labeled siRNAs by electroporated cells depends on the fluorochrome. Oligonucleotides 2003, 13:375-380.
60. Paganin-Gioanni A., Bellard E., Escoffre J.M., Rols M.P., Teissie J., Golzio M. Direct visualization at the single-cell level of siRNA electrotransfer into cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:10443-10447.
61. Paganin-Gioanni A., Bellard E., Couderc B., Teissie J., Golzio M. Tracking in vitro and in vivo siRNA electrotransfer in tumor cells. J. RNAi Gene Silencing 2008, 4:281-288.
62. Breton M., Delemotte L., Silve A., Mir L.M., Tarek M. Transport of siRNA through lipid membranes driven by nanosecond electric pulses: an experimental and computational study. J. Am. Chem. Soc. 2012, 134:13938-13941.
63. Chabot S., Orio J., Castanier R., Bellard E., Nielsen S.J., Golzio M., Teissié J. LNA-based oligonucleotide electrotransfer for miRNA inhibition. Mol. Ther. 2012, 20:1590-1598.
64. Orio J., Bellard E., Baaziz H., Pichon C., Mouritzen P., Rols M.P., Teissié J., Golzio M., Chabot S. Sub-cellular temporal and spatial distribution of electrotransferred LNA/DNA oligomer. J. RNAi Gene Silencing 2013, 9:479-485.
65. Neumann E., Shaefer-Ridder M., Wang Y., Hofschneider P.H. Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J. 1982, 1:841-845.
66. Yu M., Tan W., Lin H. A stochastic model for DNA translocation through an electropore. BBA Biomembr. 2012, 1818:2494-2501.
67. De Gennes P.G. Passive entry of a DNA molecule into a small pore. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:7262-7264.
68. Mihovilovic M., Hagerty N., Stein D. Statistics of DNA capture by a solid-state nanopore. Phys. Rev. Lett. 2013, 110:028102.
69. Smith K.C., Neu J.C., Krassowska W. Model of creation and evolution of stables electropores for DNA delivery. Biophys. J. 2004, 86:2813-2826.
70. Krassowska W., Filev P.D. Modeling electroporation in a single cell. Biophys. J. 2007, 92:404-417.
71. Neu J.C., Krassowska W. Modeling postshock evolution of large electropores. Phys. Rev. E Stat. Nonlinear Soft Matter Phys. 2003, 67:021915.
72. Hristova N.I., Tsoneva I., Neumann E. Sphingosine-mediated electroporative DNA transfer through lipid bilayers. FEBS Lett. 1997, 415:81-86.
73. Spassova M., Tsoneva I., Petrov A.G., Petkova J.I., Neumann E. Dip patch clamp currents suggest electrodiffusive transport of the polyelectrolyte DNA through lipid bilayers. Biophys. Chem. 1994, 52:267-274.
74. Kishida T., Asada H., Gojo S., Ohashi S., Shin-Ya M., Yasutomi K., Terauchi R., Takahashi K.A., Kubo T., Imanishi J., Mazda O. Sequence-specific gene silencing in murine muscle induced by electroporation-mediated transfer of short interfering RNA. J. Gene Med. 2004, 6:105-110.
75. Golzio M., Mazzolini L., Moller P., Rols M.P., Teissie J. Inhibition of gene expression in mice muscle by in vivo electrically mediated siRNA delivery. Gene Ther. 2005, 12:246-251.
76. Matsuda T., Cepko C.L. Electroporation and RNA interference in the rodent retina in vivo and in vitro. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:16-22.
77. Inoue A., Takahashi K.A., Mazda O., Terauchi R., Arai Y., Kishida T., Shin-Ya M., Asada H., Morihara T., Tonomura H., Ohashi S., Kajikawa Y., Kawahito Y., Imanishi J., Kawata M., Kubo T. Electro-transfer of small interfering RNA ameliorated arthritis in rats. Biochem. Biophys. Res. Commun. 2005, 336:903-908.
78. Takabatake Y., Isaka Y., Mizui M., Kawachi H., Shimizu F., Ito T., Hori M., Imai E. Exploring RNA interference as a therapeutic strategy for renal disease. Gene Ther. 2005, 12:965-973.
79. Akaneya Y., Jiang B., Tsumoto T. RNAi-induced gene silencing by local electroporation in targeting brain region. J. Neurophysiol. 2005, 93:594-602.
80. Takei Y., Nemoto T., Mu P., Fujishima T., Ishimoto T., Hayakawa Y., Yuzawa Y., Matsuo S., Muramatsu T., Kadomatsu K. In vivo silencing of a molecular target by short interfering RNA electroporation: tumor vascularization correlates to delivery efficiency. Mol. Cancer Ther. 2008, 7:211-221.
81. Lewis D.L., Hagstrom J.E., Loomis A.G., Wolff J.A., Herweijer H. Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat. Genet. 2002, 32:107-108.
82. McCaffrey A.P., Meuse L., Pham T.T., Conklin D.S., Hannon G.J., Kay M.A. RNA interference in adult mice. Nature 2002, 418:38-39.
83. Jackson A.L., Linsley P.S. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat. Rev. Drug Discov. 2010, 9:57-67.
84. Clape C., Fritz V., Henriquet C., Apparailly F., Fernandez P.L., Iborra F., Avances C., Villalba M., Culine S., Fajas L. miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice. PLoS One 2009, 4:e7542.
85. Kumar A., Torii T., Ishino Y., Muraoka D., Yoshimura T., Togayachi A., Narimatsu H., Ikenaka K., Hitoshi S. The Lewis X-related α1,3-fucosyltransferase, Fut10, is required for the maintenance of stem cell populations. J. Biol. Chem. 2013, 288:28859-28868.
86. Zhao X., He X., Han X., Yu Y., Ye F., Chen Y., Hoang T., Xu X., Mi Q.S., Xin M., Wang F., Appel B., Lu Q.R. MicroRNA-mediated control of oligodendrocyte differentiation. Neuron 2010, 65:612-626.
87. Zhao C., Sun G., Li S., Lang M.F., Yang S., Li W., Shi Y. MicroRNA let-7b regulates neural stem cell proliferation and differentiation by targeting nuclear receptor TLX signaling. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:1876-1881.
88. Xu J., Li R., Workeneh B., Dong Y., Wang X., Hu Z. Transcription factor FoxO1, the dominant mediator of muscle wasting in chronic kidney disease, is inhibited by microRNA-486. Kidney Int. 2012, 82:401-411.
89. Mali B., Jarm T., Snoj M., Sersa G., Miklavcic D. Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis. Eur. J. Surg. Oncol. 2013, 39:4-16.
90. Mir L.M., Devauchelle P., Quintin-Colonna F., Delisle F., Doliger S., Fradelizi D., Belehradek J., Orlowski S. First clinical trial of cat soft-tissue sarcomas treatment by electrochemotherapy. Br. J. Cancer 1997, 76:1617-1622.
91. Tozon N., Kodre V., Sersa G., Cemazar M. Effective treatment of perianal tumors in dogs with electrochemotherapy. Anticancer Res. 2005, 25:839-845.
92. Kodre V., Cemazar M., Pecar J., Sersa G., Cor A., Tozon N. Electrochemotherapy compared to surgery for treatment of canine mast cell tumors. In Vivo 2009, 23:55-62.
93. Rols M.P., Tamzali Y., Teissie J. Electrochemotherapy of horses. A preliminary clinical report. Bioelectrochemistry 2002, 55:101-105.
94. Mir L.M., Bureau M.F., Gehl J., Rangara R., Rouy D., Caillaud J.M., Delaere P., Branellec D., Schwartz B., Scherman D. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:4262-4267.
95. Vandermeulen G., Staes E., Vanderhaeghen M.L., Bureau M.F., Scherman D., Preat V. Optimisation of intradermal DNA electrotransfer for immunisation. J. Control. Release 2007, 124:81-87.
96. Isaka Y., Yamada K., Takabatake Y., Mizui M., Miura-Tsujie M., Ichimaru N., Yazawa K., Utsugi R., Okuyama A., Hori M., Imai E., Takahara S. Electroporation-mediated HGF gene transfection protected the kidney against graft injury. Gene Ther. 2005, 12:815-820.
97. Rols M.P., Delteil C., Golzio M., Dumond P., Cros S., Teissie J. In vivo electrically mediated protein and gene transfer in murine melanoma. Nat. Biotechnol. 1998, 16:168-171.
98. Spugnini E.P., Citro G., Porrello A. Rational design of new electrodes for electrochemotherapy. J. Exp. Clin. Cancer Res. 2005, 24:245-254.
99. Mazeres S., Sel D., Golzio M., Pucihar G., Tamzali Y., Miklavcic D., Teissie J. Non-invasive contact electrodes for in vivo localized cutaneous electropulsation and associated drug and nucleic acid delivery. J. Control. Release 2009, 134:125-131.
100. Chabot S., Rosazza C., Golzio M., Zumbusch A., Teissié J., Rols M.P. Nucleic acids electro-transfer: from bench to bedside. Curr. Drug Metab. 2013, 3:300-308.
101. Dalmay T. MicroRNAs and cancer. J. Intern. Med. 2008, 263:366-375.
102. Care A., Catalucci D., Felicetti F., Bonci D., Addario A., Gallo P., Bang M.L., Segnalini P., Gu Y., Dalton N.D., Elia L., Latronico M.V., Høydal M., Autore C., Russo M.A., Dorn G.W., Ellingsen O., Ruiz-Lozano P., Peterson K.L., Croce C.M., Peschle C., Condorelli G. MicroRNA-133 controls cardiac hypertrophy. Nat. Med. 2007, 13:613-618.
103. Robbins M., Judge A., Ambegia E., Choi C., Yaworski E., Palmer L., McClintock K., MacLachlan I. Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum. Gene Ther. 2008, 19:991-999.
104. Karlsen T.A., Brinchmann J.E. Liposome delivery of microRNA-145 to mesenchymal stem cells leads to immunological off-target effects mediated by RIG-I. Mol. Ther. 2013, 21:1169-1181.
105. Elmén J., Lindow M., Schütz S., Lawrence M., Petri A., Obad S., Lindholm M., Hedtjärn M., Hansen H.F., Berger U., Gullans S., Kearney P., Sarnow P., Straarup E.M., Kauppinen S. LNA-mediated microRNA silencing in non-human primates. Nature 2008, 452:896-899.
106. Mercatelli N., Coppola V., Bonci D., Miele F., Costantini A., Guadagnoli M., Bonanno E., Muto G., Frajese G.V., de Maria R., Spagnoli L.G., Farace M.G., Ciafrè S.A. The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS One 2008, 3:e4029.
107. Bellard E., Markelc B., Pelofy S., Le Guerroué F., Sersa G., Teissié J., Cemazar M., Golzio M. Intravital microscopy at the single vessel level brings new insights of vascular modification mechanisms induced by electropermeabilization. J. Control. Release 2012, 163:396-403.